Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4401377 | 0.89 | PCSK9 (0.33) | SMN1; SMN2 | |
| SCHEMBL11789090 | 0.86 | CYP3A4 (0.33) | CYP3A4TDP1 | |
| SCHEMBL11242337 | 0.86 | CSNK1E (0.38) | — | |
| SCHEMBL11245171 | 0.86 | CSNK1E (0.38) | — | |
| SCHEMBL11249146 | 0.86 | CSNK1E (0.38) | — | |
| SCHEMBL11237057 | 0.86 | CSNK1E (0.38) | — | |
| SCHEMBL11240071 | 0.86 | CSNK1E (0.38) | — | |
| SCHEMBL11233661 | 0.86 | CSNK1E (0.38) | — | |
| SCHEMBL2831139 | 0.85 | LMNA (0.33) | GPR84CYP3A4TDP1 | |
| SCHEMBL499140 | 0.85 | LMNA (0.33) | GPR84CYP3A4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632827-B2 | Antitumor agents; cytotoxic toward cells in vivo, in vitro | THE UNIVERSITY OF HONG KONG (HK) | 2009-12-15 | — | — | US | disclosed |
| US-20080166429-A1 | ANTI-CANCER PHOSPHINE CONTAINING [AuIIIm(CNC)mL]n+ COMPLEXES AND DERIVATIVES THEREOF AND METHODS FOR TREATING CANCER USING SUCH COMPOSITIONS | THE UNIVERSITY OF HONG KONG | 2008-07-10 | — | — | US | disclosed |
| US-4356324-A | CHIRAL LIGANDS FOR RHODIUM HYDROGENATION CATALYSTS | DEGUSSA AKTIENGESELLSCHAFT, A GERMAN CORP. (DE) | 1982-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080166429-A1 | ANTI-CANCER PHOSPHINE CONTAINING [AuIIIm(CNC)mL]n+ COMPLEXES AND DERIVATIVES THEREOF AND METHODS FOR TREATING CANCER USING SUCH COMPOSITIONS | NCL, NPM1, MCL1 | AOC3 1390/4885SMN1; SMN2 2789/4885FFAR1 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.